Computer scientists at the University of California, Davis, have developed a web-based contact-tracing application. The app, We-Care, allows users to check in at specific locations and notifies them if someone reporting themselves as positive for COVID-19 checks in at the same location within a certain time window.
With new seed grants from the UC Davis Office of Research’s COVID-19 Research Accelerator Funding Track (CRAFT), three teams of UC Davis engineers are applying their expertise toward the pandemic response to help people become safer, healthier and better-tested.
UC Davis leaders and researchers gathered virtually May 14 to answer the public’s questions about COVID-19, ranging from the safety of homemade masks to whether children or pets could transmit the virus.
Distinguished Professor Walter Leal brought the panel together for his second COVID-19 Public Awareness Symposium. It featured straight talk from experts about many areas that have been shrouded in confusion and conflicting information.
In the second edition of UC Davis LIVE: COVID-19, two UC Davis clinicians will talk about and take questions on the new treatments for COVID-19 being tested at UC Davis Health and other hospitals, including the experimental antiviral drug remdesivir — used to treat UC Davis’ first patient of the pandemic in March — and using plasma from people who have recovered from the novel coronavirus to treat patients.
As the disease COVID-19 spreads across the planet, scientists continue to combat the novel coronavirus (SARS-Cov-2) on all fronts. But viruses are fickle, mutating to ensure their survival as they hop hosts. Genomic mutations and natural selection could reduce the effectiveness of a potential vaccine for the novel coronavirus, and different sequence variations and strains of the virus are continuously being reported in databases like GISAID.
UC Davis scientists provide senicapoc for clinical trial in Denmark
(SACRAMENTO) — Scientists around the globe are working to identify approved and investigational drugs that can be repurposed to treat COVID-19.
UC Davis Health researchers provided one of those repurposed drugs, senicapoc, to launch a clinical trial at Aarhus University in Denmark. The study will assess whether the drug can mitigate lung damage in patients with COVID-19.
Verndari Inc., a biopharmaceutical company, announced today that it will begin preclinical testing this week at UC Davis’ Mouse Biology Program to evaluate a potential vaccine and delivery system for COVID-19.
Engineers at the University of California, Davis, are working with clinicians to create a simple, inexpensive ventilator. They have developed a prototype and plan to make plans freely available online. Versions could be in clinical use in about six months.
“This is a critical device to have. It provides the vital functions of a ventilator while being completely portable,” said Andrew Li, assistant professor in the Department of Surgery at UC Davis Health.
Expert panel on COVID-19 research, response, readiness and more!
(SACRAMENTO) — Close to 1,000 people tuned in live last Friday to a COVID-19 symposium featuring experts in immunology, infectious diseases, pathology and emergency medicine who presented the latest research and insights on coronavirus.
In its second and final round of funding, the UC Davis Office of Research has awarded ten additional COVID-19 Research Accelerator Funding Track (CRAFT) grants to campus researchers who are developing projects in response to the pandemic. Funding is provided by the Office of Research and the Provost's office with matching support from schools and colleges.
(SACRAMENTO) — UC Davis experts share their expertise nationally and internationally in the care of pregnant mothers and newborns during the COVID-19 pandemic. Here are some examples:
(SACRAMENTO) — Nearly two thirds of severely ill patients hospitalized with COVID-19 who received remdesivir on a compassionate-use basis improved, with no new concerns about safety reported during the short clinical study.
Crashes and Traffic Are Down by Half, Saving State $40 Million Per Day During Shelter-In-Place
Traffic accidents and crash-related injuries and deaths were reduced by half during the first three weeks of California’s shelter-in-place order, which began March 20. The reductions save the state an estimated $40 million per day — about $1 billion over the time period — according to an updated special report released this week from the Road Ecology Center at the University of California, Davis.